News

Mark Parry-Billings, chief development officer, and Lisa Nolan, senior vice president, Business Development, remain in their leadership roles and will work closely with company’s board of directors to

Evotec will support InterMune’s research efforts using their medicinal chemistry know-how. In addition, they will utilize their expertise and technologies in computational chemistry, protein production, X-Ray crystallography and

The Singapore-based team will consist initially of marketing managers, application specialists and field service engineers supporting BioMerieux distributors in the ASEAN (The Association of Southeast Asian Nations) countries,

Myriad is responsible for the worldwide development and commercialization of Azixa and any drug candidate that is developed from the series of compounds licensed by EpiCept to Myriad

This is claimed to be the largest single investment to date in chemicals R&D. Construction will begin in June 2008 and is expected to be completed by the

Andrew Bonfield, executive vice president and CFO, will remain in that role until Mr Huet’s arrival. He will leave the company after a period of transition to seek

High levels of FASN are present in most cancer types and are associated with diminished patient survival. Reduction of FASN activity has been reported to lead to cancer

Following successful end of Phase II discussions, FDA has approved the company’s outline plan for the Phase III clinical development program of cetilistat. This development plan comprises three

Invitrogen’s drug discovery products will be validated on selected Tecan microplate readers and instruments, starting with the Infinite series readers. Initial certifications will focus on Invitrogen’s assay systems